Literature DB >> 12022708

Tamsulosin: an overview.

Christopher Chapple1, Karl-Erik Andersson.   

Abstract

This article reviews the contemporary literature related to tamsulosin, which is now the most widely used alpha antagonist in treating benign prostatic hyperplasia. The primary emphasis of this article is on the clinical data that exist related to this agent. Currently, there are no adequate studies that effectively compare existing agents for the treatment of benign prostatic hyperplasia using a randomised, placebo-controlled design with adequate numbers and this needs to be addressed in future studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12022708     DOI: 10.1007/s00345-002-0246-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  2 in total

1.  Effects of ρ-Da1a a peptidic α(1) (A) -adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats.

Authors:  S Palea; A Maiga; V Guilloteau; M Rekik; M Guérard; C Rouget; P Rischmann; H Botto; P Camparo; P Lluel; N Gilles
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

2.  Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: A case report.

Authors:  Jae Young Lee; Ho Seok Lee; Si-Bog Park; Kyu Hoon Lee
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.